ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth - Direct Plan

Other Plans and Options
  • 0.1 %Nav, as on 27-01-2023

  • Previous Nav

  • Net Change on 27-01-2023

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

To generate long-term capital appreciation by creating a portfolio that is invested in Equity and Equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.However there can be no assurance that the investment objectives of the scheme will be realized.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
S&P BSE Health Care - TRI -2.21 -4.64 -3.24 17.30 9.26 13.16

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - Growth Jan 01, 2013 -2.60 22.01 14.48 1.11 4,563.40
SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH Jan 01, 2013 1.01 22.50 12.01 1.08 1,660.46
UTI Healthcare Fund - Direct Plan - Growth Option Jan 01, 2013 -6.49 19.16 10.88 1.46 691.46
Tata India Pharma & Healthcare Fund-Direct Plan-Growth Dec 28, 2015 -1.13 21.26 14.27 1.00 515.73

Fund Holdings as on 31-December-2022

  • Sun Pharmaceutical Industries Ltd.

  • Dr. Reddy's Laboratories Ltd.

  • Lupin Ltd.

  • Apollo Hospitals Enterprise Ltd.

  • Alkem Laboratories Ltd.

  • Sanofi India Ltd.

  • FDC Ltd.

  • Divi's Laboratories Ltd.

  • Torrent Pharmaceuticals Ltd.

  • Aurobindo Pharma Ltd.

  • Natco Pharma Ltd.

  • Cipla Ltd.

  • IPCA Laboratories Ltd.

  • Fortis Healthcare Ltd.

  • SBI Life Insurance Company Ltd.

  • TREPS

  • Indoco Remedies Ltd.

  • Gland Pharma Ltd.

  • Viatris Inc.

  • Glaxosmithkline Pharmaceuticals Ltd.

  • Aster DM Healthcare Ltd.

  • Krsnaa Diagnostics Ltd.

  • ICICI Lombard General Insurance Company Ltd.

  • Rainbow Childrens Medicare Ltd

  • Narayana Hrudayalaya Ltd.

  • Ajanta Pharma Ltd.

  • Zydus Lifesciences Ltd.

  • Biocon Ltd.

  • Windlas Biotech Ltd.

  • Dishman Carbogen Amcis Ltd.

  • Syngene International Ltd.

  • Metropolis Healthcare Ltd.

  • Cash Margin - Derivatives

  • Net Current Assets

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Insurance

  • Miscellaneous

View More

  • Cash

  • Equity

View More

About ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund

Scheme Analysis

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to ICICI Prudential Mutual Fund. It was launched on 13-Jul-2018 and currently has an AUM of ₹2,513.92 crore. ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is benchmarked against NIFTY 50 - TRI as primary index and S&P BSE Health Care - TRI as secondary index.

The NAV of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund ended up ₹0.02(0.1%)yesterday to ₹19.82.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Ltd., and

The ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is managed by Dharmesh Kakkad .

Fund House Contact

One BKC, A - Wing 13th Floor, Bandra Kurla Complex, Bandra (East) Mumbai - 400 051

+91 (22) 2652 5000
enquiry@icicipruamc.com
+91 (22) 2652 8100